TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18757456

Group type: EXPERIMENTAL
Intervention: Serum CC-16 levels in individuals with COPD (n=1888)
Number of subjects: 2652

Group type: EXPERIMENTAL
Intervention: Serum CC-16 levels in current smokers with COPD
Number of subjects: 2652

Group type: EXPERIMENTAL
Intervention: Serum CC-16 levels in former smokers with COPD
Number of subjects: 2652

Group type: COMPARATOR
Intervention: Serum CC-16 levels in individuals without airflow obstruction (n=296)
Number of subjects: 2652

Group type: COMPARATOR
Intervention: Serum CC-16 levels in non-smokers (n=201)
Number of subjects: 2652

Group type: EXPERIMENTAL
Intervention: Correlation of serum CC-16 levels with age and gender in COPD subjects
Number of subjects: 2652

Group type: EXPERIMENTAL
Intervention: Serum CC-16 levels in individuals with GOLD stage II and III COPD
Number of subjects: 2652

Group type: EXPERIMENTAL
Intervention: Serum CC-16 levels in former smokers with reversible airflow obstruction
Number of subjects: 2652
Study: 18758745

Group type: EXPERIMENTAL
Intervention: Weight-reduction intervention (diet-induced weight loss) for 33 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no weight-reduction intervention)
Number of subjects: 34
Study: 18761748

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rituximab treatment in aggregate-containing tissues
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rituximab treatment in aggregate-containing synovia
Number of subjects: 14

Group type: COMPARATOR
Intervention: RA synovia compared with serum
Number of subjects: 14
Study: 18762599

Group type: EXPERIMENTAL
Intervention: Maternal age 12 to 15 years
Number of subjects: 10745

Group type: EXPERIMENTAL
Intervention: Maternal age younger than 25 years
Number of subjects: 10745

Group type: EXPERIMENTAL
Intervention: Younger mothers (under 25)
Number of subjects: 10745
Study: 18765432

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus simvastatin
Number of subjects: 1873

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1873

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1873
Study: 18769450

Group type: EXPERIMENTAL
Intervention: BACH2 siRNA transfection in UCB CD4(+) T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: UCB CD4(+) T cells
Number of subjects: 0
Study: 18769731

Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin (r-metHuLeptin) at physiologic replacement doses of 0.03 mg/kg/day
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin (r-metHuLeptin)
Number of subjects: 1
Study: 18771667

Group type: EXPERIMENTAL
Intervention: 10 mg/kg/day Silibinin (IV) for 7 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day Silibinin (IV) for 14 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10 mg/kg/day Silibinin (IV) for 14 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 15 mg/kg/day Silibinin (IV) for 14 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 mg/kg/day Silibinin (IV) for 14 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined Silibinin/PegIFN/RBV
Number of subjects: 36
Study: 18774548

Group type: EXPERIMENTAL
Intervention: 3D OCT-1000 (Fourier-domain OCT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Stratus OCT (Time-domain OCT)
Number of subjects: 36
Study: 18776118

Group type: EXPERIMENTAL
Intervention: Angiotensin II blockers added to ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual RAAS blockade (ACE inhibitors + Angiotensin II blockers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors alone
Number of subjects: 0
Study: 18776138

Group type: EXPERIMENTAL
Intervention: Ghrelin infusion (5 pmol . kg(-1) . min(-1))
Number of subjects: 14
Study: 18778241

Group type: EXPERIMENTAL
Intervention: HAART including nevirapine (96%) or efavirenz (4%)
Number of subjects: 596
Study: 18778916

Group type: EXPERIMENTAL
Intervention: Lamotrigine monotherapy
Number of subjects: 54
Study: 18779469

Group type: EXPERIMENTAL
Intervention: Dalteparin sodium, 5000 IU once daily
Number of subjects: 138
Study: 18780832

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Prednisolone incubation
Number of subjects: 237
Study: 18781879

Group type: COMPARATOR
Intervention: 5 mg/kg of L-AmB alone (group A)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 5 mg/kg of L-AmB followed by miltefosine for 10 days (group B)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 5 mg/kg of L-AmB followed by miltefosine for 14 days (group C)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 3.75 mg/kg of L-AmB followed by miltefosine for 14 days (group D)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 5 mg/kg of L-AmB followed by miltefosine for 7 days (group E)
Number of subjects: 226
Study: 18784101

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab (cisplatin or carboplatin plus fluorouracil with cetuximab at 400 mg/m² initially, then 250 mg/m² weekly)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 442

Group type: COMPARATOR
Intervention: Chemotherapy alone (cisplatin or carboplatin plus fluorouracil)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 442
Study: 18784623

Group type: EXPERIMENTAL
Intervention: 2.5 mg bevacizumab intravitreally in the worst eye
Number of subjects: 23
Study: 18786266

Group type: EXPERIMENTAL
Intervention: DrotAA (24 microg/kg per hour) infused for 96 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18786301

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS Therapy)
Number of subjects: 0
Study: 18791359

Group type: EXPERIMENTAL
Intervention: Severe burn injury
Number of subjects: 242
Study: 18794207

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-6 mg/day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Molindone (10-140 mg/day, plus 1 mg/day of benztropine)
Number of subjects: 119
Study: 18794456

Group type: EXPERIMENTAL
Intervention: Topical estradiol 0.01%, 0.1%, 1%, or 2.5%
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 70
Study: 18794722

Group type: EXPERIMENTAL
Intervention: 22GA genotype (n=5)
Number of subjects: 96

Group type: COMPARATOR
Intervention: GG genotype (n=35)
Number of subjects: 96
Study: 18799002

Group type: EXPERIMENTAL
Intervention: Obesity intervention program 'Obeldicks'
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Risk A-allele of rs9939609
Number of subjects: 207
Study: 18799354

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle changes
Number of subjects: 30
Study: 18799557

Group type: EXPERIMENTAL
Intervention: CT colonography
Number of subjects: 2600
Study: 18799726

Group type: EXPERIMENTAL
Intervention: Lenalidomide + dexamethasone
Number of subjects: 704

Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 704
Study: 18803826

Group type: EXPERIMENTAL
Intervention: New-generation lens (VARILUX PANAMIC ORMA CRIZAL)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Older-generation lens (VARILUX CONFORT ORMA CRIZAL)
Number of subjects: 127
Study: 18805103

Group type: EXPERIMENTAL
Intervention: Routine fasting (abstinence from food and drink)
Number of subjects: 448

Group type: COMPARATOR
Intervention: LDS members
Number of subjects: 448

Group type: COMPARATOR
Intervention: Non-LDS members
Number of subjects: 448
Study: 18805967

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatments
Number of subjects: 0
Study: 18806079

Group type: EXPERIMENTAL
Intervention: Higher serum TSH levels at 4 weeks postpartum
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Positive postnatal thyroid antibody tests
Number of subjects: 51
Study: 18809192

Group type: EXPERIMENTAL
Intervention: Mansonella perstans infection in Mukono community
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Mansonella perstans infection in Luwero community
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Age group 1-4 years in Mukono
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Age group 1-4 years in Luwero
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Age group 15-19 years in Mukono
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Age group 15-19 years in Luwero
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Geometric mean mf intensity in Mukono
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Geometric mean mf intensity in Luwero
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Overall clinical parameters
Number of subjects: 1566
Study: 18812445

Group type: EXPERIMENTAL
Intervention: Ambrisentan 2.5 mg qd for 4 weeks followed by 5 mg/d for 8 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ambrisentan treatment
Number of subjects: 36
Study: 18813343

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 74
Study: 18816386

Group type: EXPERIMENTAL
Intervention: 100 μg IT morphine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 200 μg IT morphine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 300 μg IT morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (100 μg IT morphine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (200 μg IT morphine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (300 μg IT morphine)
Number of subjects: 60
Study: 18816600

Group type: EXPERIMENTAL
Intervention: Sensory evoked potentials (SEPs) assessment in polio survivors
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) evaluation
Number of subjects: 22
Study: 18823688

Group type: EXPERIMENTAL
Intervention: Daily hemodialysis (DHD) 6 times/week with the NxStage System One device
Number of subjects: 500

Group type: COMPARATOR
Intervention: Thrice-weekly in-center hemodialysis (HD)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Daily hemodialysis (DHD)
Number of subjects: 500
Study: 18824593

Group type: EXPERIMENTAL
Intervention: High-dose, single-agent lenalidomide
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 2
Study: 18824594

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (ASCT)
Number of subjects: 7
Study: 18825363

Group type: EXPERIMENTAL
Intervention: Insulin-resistant (IR) individuals
Number of subjects: 33

Group type: COMPARATOR
Intervention: Insulin-sensitive (IS) individuals
Number of subjects: 33
Study: 18829231

Group type: EXPERIMENTAL
Intervention: Seated ABI measurement using corrected ankle pressure formula
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supine ABI measurement
Number of subjects: 100
Study: 18832245

Group type: EXPERIMENTAL
Intervention: Maraviroc plus optimized background therapy (OBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus optimized background therapy (OBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maraviroc plus OBT
Number of subjects: 0
Study: 18834580

Group type: EXPERIMENTAL
Intervention: Dorzolamide eye drops
Number of subjects: 7
Study: 18838471

Group type: EXPERIMENTAL
Intervention: High-risk cytogenetics and/or at least two of the following: age >= 75 years, performance status >= 2, white cell count >= 50 x 10(9)/L
Number of subjects: 416

Group type: COMPARATOR
Intervention: Standard intensive chemotherapy
Number of subjects: 416
Study: 18838477

Group type: EXPERIMENTAL
Intervention: Imatinib 600 mg daily
Number of subjects: 92
Study: 18842912

Group type: EXPERIMENTAL
Intervention: Surgical tracheobronchoplasty
Number of subjects: 77
Study: 18845370

Group type: EXPERIMENTAL
Intervention: eGFR(cysC) of 60 to 75 mL/min/1.73 m(2)
Number of subjects: 4971

Group type: EXPERIMENTAL
Intervention: eGFR(cysC) less than 60 mL/min/1.73 m(2)
Number of subjects: 4971
Study: 18846045

Group type: EXPERIMENTAL
Intervention: Obese cohort
Number of subjects: 70
Study: 18849604

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced cardiac magnetic resonance (ceCMR) scanning before discharge
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard transthoracic echocardiography (TTE)
Number of subjects: 100
Study: 18851740

Group type: EXPERIMENTAL
Intervention: Innovative physiological index approach (SPINA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observation of variables quantifying distinct components of NTIS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative follow-up of NTIS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuropsychological impact assessment of NTIS
Number of subjects: 0
Study: 18851761

Group type: EXPERIMENTAL
Intervention: d4T, 3TC and NVP
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: d4T, 3TC and NVP with rifampicin
Number of subjects: 140

Group type: COMPARATOR
Intervention: d4T, 3TC and NVP without rifampicin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: d4T
Number of subjects: 140
Study: 18851871

Group type: EXPERIMENTAL
Intervention: Algorithm utilizing HE4 and CA125
Number of subjects: 531
Study: 18852348

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (3 to 9 g per night in split doses over 6 weeks)
Number of subjects: 38
Study: 18854394

Group type: EXPERIMENTAL
Intervention: Vorinostat (200 mg twice daily for 2 weeks, followed by 1 week off therapy)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Vorinostat (200 mg twice daily)
Number of subjects: 19
Study: 18854428

Group type: EXPERIMENTAL
Intervention: r-metHuLeptin
Number of subjects: 3

Group type: COMPARATOR
Intervention: Off treatment (no r-metHuLeptin)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Off-leptin OGTT
Number of subjects: 3
Study: 18856012

Group type: EXPERIMENTAL
Intervention: Higher dose continuous veno-venous hemodiafiltration (CVVHDF) at an effluent rate of 40 ml/kg/h
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Standard-dose continuous veno-venous hemodiafiltration (CVVHDF) at an effluent rate of 25 ml/kg/h
Number of subjects: 1500
Study: 18856162

Group type: EXPERIMENTAL
Intervention: Efalizumab therapy
Number of subjects: 4
Study: 18922099

Group type: EXPERIMENTAL
Intervention: ATRA (22.5 mg/m2 twice daily for 2 days)
Number of subjects: 22
Study: 18926148

Group type: EXPERIMENTAL
Intervention: Use of statins and beta-blockers at discharge
Number of subjects: 4402

Group type: EXPERIMENTAL
Intervention: C-index of the model
Number of subjects: 4402

Group type: EXPERIMENTAL
Intervention: Point scoring system based on 8 identified factors
Number of subjects: 4402

Group type: EXPERIMENTAL
Intervention: 60- to 90-day postdischarge mortality rate
Number of subjects: 4402

Group type: EXPERIMENTAL
Intervention: Rehospitalization rate
Number of subjects: 4402

Group type: EXPERIMENTAL
Intervention: Factors predicting early postdischarge mortality
Number of subjects: 4402

Group type: EXPERIMENTAL
Intervention: Combined endpoint of death or rehospitalization
Number of subjects: 4402
Study: 18928574

Group type: EXPERIMENTAL
Intervention: Specific acupoints of Shaoyang meridians (120 patients)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Non-specific acupoints of Shaoyang meridians (120 patients)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Acupoints of other meridians (120 patients)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Non-acupoints control group (120 patients)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 480
Study: 18931344

Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate (GX15-070) administered at doses ranging from 3.5 to 14 mg/m² as a 1-hour infusion and from 20 to 40 mg/m² as a 3-hour infusion every 3 weeks.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate (GX15-070) administered at maximum tolerated dose (MTD) of 28 mg/m² over 3 hours every 3 weeks.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate (GX15-070) administered to 26 patients.
Number of subjects: 26
Study: 18936319

Group type: EXPERIMENTAL
Intervention: Standard-position group (both arms raised above shoulder)
Number of subjects: 177

Group type: COMPARATOR
Intervention: One-arm group (one arm raised, one arm down)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Two-arm group (both arms down)
Number of subjects: 177
Study: 18941347

Group type: EXPERIMENTAL
Intervention: New therapies using hormone agonists for treating uremic toxicity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uremic toxins (rho-Cresol sulfate and indoxyl sulfate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Impaired immunity in ESRD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disordered feeding circuits in ESRD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mortality in ESRD
Number of subjects: 0
Study: 18942885

Group type: EXPERIMENTAL
Intervention: Intermittent, CD4-guided antiretroviral treatment (ART) - Drug Conservation (DC)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Continuous ART - Viral Suppression (VS)
Number of subjects: 499
Study: 18945255

Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day) for 48 weeks
Number of subjects: 28
Study: 18945347

Group type: EXPERIMENTAL
Intervention: 80% oxygen (FiO(2) = 0.80)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: 30% oxygen (FiO(2) = 0.30)
Number of subjects: 1400
Study: 18948732

Group type: EXPERIMENTAL
Intervention: Direct ELISA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single epitope-based inhibition ELISA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pseudovirion-based neutralization assay (PBNA)
Number of subjects: 0
Study: 18948801

Group type: EXPERIMENTAL
Intervention: High volume surgeons (more than 10 cases)
Number of subjects: 871

Group type: COMPARATOR
Intervention: Medium volume surgeons (6-10 cases)
Number of subjects: 871

Group type: COMPARATOR
Intervention: Low volume surgeons (5 or fewer cases)
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: All surgeon volumes
Number of subjects: 871
Study: 18950491

Group type: EXPERIMENTAL
Intervention: Surgical Venae Sectio for TIAP insertion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Punction of V. Subclavia for TIAP insertion
Number of subjects: 100
Study: 18950508

Group type: EXPERIMENTAL
Intervention: Recommended dairy (> 3 servings/d)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Low dairy (< 1 dairy serving/d)
Number of subjects: 338
Study: 18952682

Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 179

Group type: COMPARATOR
Intervention: Flat inserts
Number of subjects: 179

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 179

Group type: COMPARATOR
Intervention: Physiotherapy plus foot orthoses
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: All groups (Foot orthoses, Flat inserts, Physiotherapy, Physiotherapy plus foot orthoses)
Number of subjects: 179
Study: 18952896

Group type: EXPERIMENTAL
Intervention: Folate-linked radioimaging agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folate-linked dyes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inflammatory stimuli (saline, thioglycolate, zymosan, heat-killed or live bacteria)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FR(+) macrophages
Number of subjects: 0
Study: 18954442

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study: 18954843

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 43
Study: 18955445

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily) with temozolomide (TMZ) (75 mg/m² daily) and radiotherapy (RT) (60 Gy)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily) with temozolomide (TMZ) (200 mg/m² daily for 5 days every 28 days)
Number of subjects: 97

Group type: COMPARATOR
Intervention: RT/TMZ (European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada trial 26981/22981)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Nitrosourea-based chemotherapy (historical controls)
Number of subjects: 97
Study: 18957506

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 microg twice daily for 15 d
Number of subjects: 39
Study: 18971421

Group type: EXPERIMENTAL
Intervention: CD45 monoclonal antibodies (mAbs)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Autologous EBV-specific cytotoxic T cells (CTL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CD45 monoclonal antibodies (mAbs) followed by EBV-specific CTL infusion
Number of subjects: 8
Study: 18974373

Group type: EXPERIMENTAL
Intervention: Ipilimumab (0.1 to 3.0 mg/kg single infusion)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ipilimumab (3.0 mg/kg single infusion)
Number of subjects: 29
Study: 18976472

Group type: EXPERIMENTAL
Intervention: OROS(R) hydromorphone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Controlled-release morphine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Immediate-release hydromorphone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sustained-release hydromorphone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sustained-release morphine
Number of subjects: 200
Study: 18976849

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) doses greater than 0.4 mg/kg/d
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg/d) alone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 7
Study: 18977647

Group type: EXPERIMENTAL
Intervention: T-SPOT.TB assay at T0 (initial treatment)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: T-SPOT.TB assay at TE (end of treatment)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: T-SPOT.TB assay at TE+6 (6 months after treatment)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Comparison of SFUs between T0 and TE
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Outcome of patients with increased SFUs between T0 and TE
Number of subjects: 62
Study: 18978345

Group type: EXPERIMENTAL
Intervention: Periocular topotecan (0.5 mg starting dose, escalated to 2 mg max dose)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Periocular topotecan
Number of subjects: 5
Study: 18980675

Group type: EXPERIMENTAL
Intervention: Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas plus ILM peeling
Number of subjects: 0
Study: 18981291

Group type: EXPERIMENTAL
Intervention: Romiplostim (AMG531)
Number of subjects: 142